News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AllaChem Announces the Completion of Pre-Clinical Studies With ONC1-13B, a New Effective Anti-Androgen for the Treatment of Prostate and Breast Cancers



8/5/2013 8:52:31 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Hallandale Beach, Fl – July 28, 2013 - Alla Chem, LLC announced today the completion of pre-clinical studies with ONC1-13B, a next in-class small molecule androgen receptor inhibitor for the treatment of prostate and breast cancers. The results will be reported at the 3rd World Congress on Cancer Science & Therapy, October 21-23, 2013, in San Francisco . The submission package for the phase I/II clinical studies is under review by the Russian Regulatory Agencies.

The phase I / II clinical studies will be conducted in 12-24 volunteers with progressive metastatic castration-resistant prostate cancer in 4-6 clinical sites in the Russian Federation . The studies will evaluate ONC1-13B efficacy, safety, tolerability and pharmacokinetics upon single and repeated oral administration of 40, 80, 160, and 320 mg doses.

CONTACT:

Alena Ivachtchenko, MBA

Director Business Development

Phone: 1-858-35-6627

E-mail: alena.ivachtchenko@allachem.com; av@allachem.com

www.allachem.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Alla Chem
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES